CTOs on the Move

Anavasi Diagnostics

www.anavasi.com

 
Anavasi Diagnostics is a medical technology company focused on saving lives by developing novel molecular diagnostic testing using a proprietary patent-pending reverse transcriptase methodology. It was founded by world-leading university researchers, top medical device and clinical diagnostics engineering and design executives, manufacturing experts and a former Microsoft software veteran. Throughout their careers, the team has altogether been responsible for the introduction of more than forty medical/diagnostic products and over 350 peer-reviewed research publications.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.anavasi.com
  • 4000 Mason Road
    Seattle, WA USA 98195
  • Phone: 888.262.8274

Executives

Name Title Contact Details

Similar Companies

PartsSource

PartsSource is the nation`s only multi-modality, multi-vendor supplier of medical replacement parts.

Biomerica

Biomerica is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Cardiac Therapeutics Inc

Advanced Cardiac Therapeutics, Inc. is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. AFIB is characterized by an irregular, often rapid heart rate that commonly causes poor systemic blood flow. The Company`s mission is to dramatically improve the treatment of AFIB through the introduction of products based on its proprietary catheter and generator system. ACT`s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation and contact sensing. The ACT system is not currently approved for commercial use.

Mangar Industries

Mangar Industries is a Doylestown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Valeritas

Valeritas is committed to developing and commercializing innovative treatment solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of Type 2 diabetes. Valeritas` portfolio is headlined by the V-Go® disposable insulin delivery device, which is being commercialized and reimbursed in a specialty pharmaceutical model and is distributed through retail pharmacy.